Ophthalmology Doctors in Clayton, MO Accepting Medicare

1 Ophthalmology doctors found. Showing 1 - 1

James Charles Bobrow, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 121 Hunter Ave, Suite 102, Clayton, MO 63124 Phone: 314-721-1140    Fax: 314-721-1863

News Archive

PaedRegCliNet promotes development of medications for children

Many of the medications used to treat children have been developed almost exclusively for adults and approved for them. This is why pediatricians have been demanding for decades that medications be tailored specifically to the needs of the child's body and adequately tested on children. A regulation from the European Commission called the Pediatric Regulation has set out to solve this problem. Clinical studies involving children should ultimately give way to medications tailored for this age group.

Final patient completion of phase II study of TR040303 in patients treated for acute myocardial infarction announced by Trophos

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the final patient completion of a phase II study of TR040303 in patients treated for acute myocardial infarction (MI). Outcome data of this study is expected to be available towards the end of 2013.

Treatment with atorvastatin cut incidence of stroke by almost a half

Patients with Type 2 diabetes and a CV risk factor would benefit from a cholesterol-lowering medicine according to results from the first ever specifically designed UK primary prevention statin trial announced today at the American Diabetes Association (ADA)2.

Acute sleep loss impacts working memory differently in women and men

Over the last few decades, a wealth of evidence has accumulated to suggest that a lack of sleep is bad for mind and body. Working memory is important for keeping things in mind for briefer periods of time, which thereby facilitates reasoning and planning.

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults. If approved, this would be the second product that contains a complete HIV treatment regimen in a single once-daily tablet.

Read more Medical News

› Verified 4 days ago